Merck Oncology Clinical Trials for Lung Cancer

Merck is passionate about improving health. We are committed to accelerating every step in the journey in our quest to bring treatment options to people with cancer. These clinical trials for lung cancer are investigating different study medications alone, or in combination with other study medications, or standard of care therapy, to see if they can help prevent, find, or treat cancer. 

Participating in a clinical trial is an important decision. Anyone participating in a trial should know as much as possible about what is being studied, what risks are involved and what potential benefits may be gained before deciding to enroll. If you are interested in participating in a clinical trial, please talk to your doctor first.

You can also call our clinical trial information center at 1-888-577-8839 to learn more.

Active Clinical Trials

Trial Description Trial Number Condition Phase Status
Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab With or Without Lenvatinib as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer
7902-006 Nonsquamous Non-small Cell Lung Cancer Phase 3 Recruiting
Efficacy and Safety Study of Pembrolizumab With or Without Lenvatinib in Adults With Programmed Cell Death-Ligand 1 -Positive Treatment-naïve Non-small Cell Lung Cancer
7902-007 Non-small Cell Lung Cancer Phase 3 Recruiting
Efficacy and Safety of Pembrolizumab With Lenvatinib vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer and Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy
7902-008 Metastatic Non-Small Cell Lung Cancer Phase 3 Recruiting
Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line Metastatic Nonsquamous Non-Small-Cell Lung Cancer
KEYLYNK-006 Carcinoma, Non-squamous Non-small-cell Lung Phase 3 Recruiting
A Study of Pembrolizumab With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer
KEYLYNK-008 Carcinoma, Squamous Cell, Non-small-cell Lung Phase 3 Recruiting
Study of Pembrolizumab vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy
091 Non-small Cell Lung Cancer Phase 3 Recruiting
Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-small Cell Lung Cancer
598 Carcinoma, Non-Small-Cell Lung Phase 3 Active, not recruiting
Efficacy and Safety of Pembrolizumab With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage IIB or IIIA Non-small Cell Lung Cancer
671 Early-stage Non-small Cell Lung Cancer Phase 3 Recruiting
Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI) -Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)
789 Non-small Cell Lung Cancer Phase 3 Recruiting
A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC.
799 Non-small Cell Lung Cancer Phase 2 Recruiting
Efficacy and Safety Study of Stereotactic Body Radiotherapy With or Without Pembrolizumab in Adults With Medically Inoperable Stage I or IIA Non-Small Cell Lung Cancer
867 Non-Small Cell Lung Cancer Phase 3 Recruiting
Study of Two Doses of Pembrolizumab Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer
010 Non Small Cell Lung Cancer (NSCLC) Phase 2/Phase 3 Active, not recruiting
Study of Pembrolizumab Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer
011
  • Solid Tumor
  • Non-small Cell Lung Cancer
  • Small Cell Lung Cancer
Phase 1 Active, not recruiting
A Study of Pembrolizumab in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer
021 Non-small Cell Lung Carcinoma Phase 1/Phase 2 Active, not recruiting
Study of Pembrolizumab Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer
024 Non-Small Cell Lung Carcinoma Phase 3 Active, not recruiting
Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Pembrolizumab in Chinese Participants With Non-Small-Cell Lung Cancer
032 Non-Small-Cell Lung Cancer Phase 1 Active, not recruiting
Study of Pembrolizumab Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 -Positive Advanced or Metastatic Non-Small Cell Lung Cancer
042 Non-small Cell Lung Cancer Phase 3 Active, not recruiting
Study of Platinum+Pemetrexed Chemotherapy With or Without Pembrolizumab in Participants With First Line Metastatic Non-squamous Non-small Cell Lung Cancer
189 Non-Small-Cell Lung Carcinoma Phase 3 Active, not recruiting
A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer
407 Non-small Cell Lung Cancer Phase 3 Active, not recruiting
A Study of Pembrolizumab in Combination With Etoposide/Platinum for Participants With Extensive Stage Small Cell Lung Cancer
604
  • Small Cell Lung Cancer
  • SCLC
Phase 3 Active, not recruiting

Clinical Trials: Important Information to Consider

There is a lot to consider when deciding whether to participate in a clinical study. Any clinical study includes risks, which the study doctor will review with you. Make sure you understand the risks before participating.